| 查看: 810 | 回复: 7 | ||||
[交流]
STM：靶向作用脂肪激素或可开发出治疗2型糖尿病的新型疗法
|
||||
|
12月23日，来自哈佛大学的一个研究团队通过研究描述了一种临床前的方法或可帮助治疗2型糖尿病、脂肪肝及其它代谢性疾病，文章中研究者开发了一种抗体，其可以改善通过靶向作用脂肪组织中名为aP2（FABP4）的激素来帮助改善机体的葡萄糖调节，并且降低肥胖小鼠集体的脂肪肝症状。 Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes http://stm.sciencemag.org/content/7/319/319ra205 Kill the messenger A variety of metabolic messengers—many from adipose tissue itself—controls the energy state of organs and organisms. Recently, researchers showed that the fatty acid binding protein aP2, once thought to live and work only in the cytoplasm, is also secreted by adipose tissue and spurs metabolic changes in other organs. Now, Burak and colleagues test whether secreted aP2 can serve as a therapeutic target for type 2 diabetes. In mice, the secreted form of aP2 regulates glucose production in liver, systemic glucose homeostasis, and insulin resistance. Serum levels of aP2 were shown to be elevated in obese mice and humans and to correlate with metabolic complications. The authors identified a monoclonal antibody to aP2 that lowered fasting blood glucose, increased insulin sensitivity, and lowered both fat mass and fatty liver (steatosis) in obese mouse models, relative to a control antibody, but not in aP2-deficient mice. The antidiabetic effects of the therapeutic antibody were linked to the regulation of hepatic glucose output and peripheral glucose utilization. Together, these findings suggest that an aP2-targeted antibody that kills the messenger is a viable approach for diabetes treatment. Abstract The lipid chaperone aP2/FABP4 has been implicated in the pathology of many immunometabolic diseases, including diabetes in humans, but aP2 has not yet been targeted for therapeutic applications. aP2 is not only an intracellular protein but also an active adipokine that contributes to hyperglycemia by promoting hepatic gluconeogenesis and interfering with peripheral insulin action. Serum aP2 levels are markedly elevated in mouse and human obesity and strongly correlate with metabolic complications. These observations raise the possibility of a new strategy to treat metabolic disease by targeting serum aP2 with a monoclonal antibody (mAb) to aP2. We evaluated mAbs to aP2 and identified one, CA33, that lowered fasting blood glucose, improved systemic glucose metabolism, increased systemic insulin sensitivity, and reduced fat mass and liver steatosis in obese mouse models. We examined the structure of the aP2-CA33 complex and resolved the target epitope by crystallographic studies in comparison to another mAb that lacked efficacy in vivo. In hyperinsulinemic-euglycemic clamp studies, we found that the antidiabetic effect of CA33 was predominantly linked to the regulation of hepatic glucose output and peripheral glucose utilization. The antibody had no effect in aP2-deficient mice, demonstrating its target specificity. We conclude that an aP2 mAb–mediated therapeutic constitutes a feasible approach for the treatment of diabetes. |
回复此楼» 收录本帖的淘帖专辑推荐
 新药资讯 |
» 猜你喜欢
[求助] 流式死活染 & 单细胞门控设置被质疑，如何优化并解释？
已经有1人回复
-
蛋白稳定性实验与功能实验不一致
已经有11人回复
-
药理学论文润色/翻译怎么收费?
已经有239人回复
-
第4年了，马上40了，可能我与国基确实无缘吧。。。
已经有12人回复
-
2026年申博药学专业
已经有1人回复
-
药学专硕申博
已经有18人回复
-
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
医药研发数据库资源
已经有4人回复
-
分子对接相关经验分享
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
2027年博士生（硕博连读/直博）吉林大学-苏州国家实验室光电半导体智能设计与应用团队
+1/474
-
药化高级研究员
+1/81
-
华东理工大学 生物工程学院 生物反应器工程国家重点室 博士后招聘
+1/77
-
Postdoctoral fellow in Medicinal Chemistry, McGill University
+1/71
-
中科院东莞材料所依托中科大招收2027届推免生
+1/35
-
有机合成高级研究员
+1/31
-
大连理工大学化学学院界面介导黏附与组装课题组招收2027级推免生/考研生
+1/29
-
西安交通大学补亚忠课题组招聘2027年博士生
+1/27
-
西湖大学拓扑光学、非厄米光学、太赫兹方向博士后招聘（长期有效）
+5/20
-
诚征女友( 西安 )
+1/19
-
新西兰坎特伯雷大学招博士后
+1/6
-
西安交通大学补亚忠课题组招收申请考核制博士生
+2/6
-
（Scopus期刊）Biofunctional Materials《生物功能性材料》招募青年编委及征稿
+1/4
-
准现货/原装全新超微整机8x NVIDIA HGX A100 80G
+1/4
-
2027年硕士推免生 招生--哈尔滨工业大学王磊
+1/4
-
国际 EI 会议征稿进行时
+1/2
-
分不清 EI 会议 CA 和 JA？90% 投稿人踩过的检索大坑
+1/2
-
这些Scopus收录的英文国际期刊正在征稿（快速审稿）2026年底前免APC！
+1/2
-
中科院大连化物所诚聘博士后/科研助理/项目聘用人员
+1/1
-
浙江大学王宇课题组诚聘博士后/博士研究生/科研助理（招聘长期有效）
+1/1
8楼2016-01-10 22:43:00
简单回复
jiantu2楼
2015-12-29 10:32
回复
linglingchen(金币+1): 谢谢参与
liangbk3楼
2015-12-29 11:05
回复
linglingchen(金币+1): 谢谢参与
tzynew4楼
2015-12-29 12:50
回复
linglingchen(金币+1): 谢谢参与
假大空5楼
2015-12-29 13:24
回复
linglingchen(金币+1): 谢谢参与
2015-12-29 13:42
回复
linglingchen(金币+1): 谢谢参与
好
2016-01-09 22:32
回复
1
